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Abstract
Background: Advances in biomedical science and technology have resulted in dramatic improvements in the healthcare
of pediatric chronic conditions. With enhanced survival, health-related quality of life (HRQOL) issues have become more
salient. The objectives of this study were to compare generic HRQOL across ten chronic disease clusters and 33 disease
categories/severities from the perspectives of patients and parents. Comparisons were also benchmarked with healthy
children data.
Methods: The analyses were based on over 2,500 pediatric patients from 10 physician-diagnosed disease clusters and
33 disease categories/severities and over 9,500 healthy children utilizing the PedsQL™ 4.0 Generic Core Scales. Patients
were recruited from general pediatric clinics, subspecialty clinics, and hospitals.
Results: Pediatric patients with diabetes, gastrointestinal conditions, cardiac conditions, asthma, obesity, end stage renal
disease, psychiatric disorders, cancer, rheumatologic conditions, and cerebral palsy self-reported progressively more
impaired overall HRQOL than healthy children, respectively, with medium to large effect sizes. Patients with cerebral
palsy self-reported the most impaired HRQOL, while patients with diabetes self-reported the best HRQOL. Parent
proxy-reports generally paralleled patient self-report, with several notable differences.
Conclusion: The results demonstrate differential effects of pediatric chronic conditions on patient HRQOL across
diseases clusters, categories, and severities utilizing the PedsQL™ 4.0 Generic Core Scales from the perspectives of
pediatric patients and parents. The data contained within this study represents a larger and more diverse population of
pediatric patients with chronic conditions than previously reported in the extant literature. The findings contribute
important information on the differential effects of pediatric chronic conditions on generic HRQOL from the
perspectives of children and parents utilizing the PedsQL™ 4.0 Generic Core Scales. These findings with the PedsQL™
have clinical implications for the healthcare services provided for children with chronic health conditions. Given the
degree of reported impairment based on PedsQL™ scores across different pediatric chronic conditions, the need for
more efficacious targeted treatments for those pediatric patients with more severely impaired HRQOL is clearly and
urgently indicated.
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Advances in biomedical science and technology have
resulted in dramatic improvements in the healthcare of
pediatric chronic conditions. Many children who either
died early in life or were institutionalized are now living
well into adulthood and functioning in the community
[1]. With this improvement in life status, health-related
quality of life (HRQOL) issues have become more salient,
particularly given that this survival is accompanied by sig-
nificant ongoing healthcare needs related to their chronic
condition [2]. Simply surviving is not sufficient; the qual-
ity of survival has emerged as a fundamental focus of com-
prehensive healthcare [3].
The last decade has evidenced a dramatic increase in the
development and utilization of pediatric HRQOL meas-
ures in an effort to improve patient health and well-being
and to determine the value of healthcare services [3,4]. A
generic HRQOL instrument must be multidimensional,
consisting at the minimum of the physical, psychological
(including emotional and cognitive), and social health
dimensions delineated by the World Health Organization
[5,6]. While disease-specific measures may enhance meas-
urement sensitivity for health domains germane to a par-
ticular chronic condition, the utilization of a generic
HRQOL instrument enables comparisons across chronic
conditions and benchmarking with healthy population
samples [7-10].
Although a number of studies have investigated the
generic HRQOL of adult patients across numerous
chronic conditions, typically utilizing the SF-36 [11,12],
there has been a relative absence of similar studies which
have studied pediatric generic HRQOL across multiple
pediatric chronic conditions utilizing the same measure-
ment instrument in which both pediatric patient self-
report and parent-proxy reported are obtained [4,13].
A study by Sprangers et al. [14] of generic HRQOL (SF-36)
across numerous adult chronic conditions serves as a use-
ful analytic model. These investigators aggregated disease
categories (e.g., rheumatoid arthritis, osteoarthritis) into
13 disease clusters (e.g., musculoskeletal conditions). We
modified this overall scheme given the different nature
and prevalence of pediatric chronic conditions. Addition-
ally, to identify the specific effects of each condition on
HRQOL, we excluded patients with comorbid conditions
[15] (except for the psychiatric sample in which this was
not possible), and included only patients with physician-
diagnosed conditions. We further analyzed the effects of
disease severity on HRQOL.
The objectives of the present study were to compare
generic HRQOL across ten pediatric chronic disease clus-
ters and 33 disease categories/severities utilizing the Ped-
sQL™ 4.0 Generic Core Scales from the perspectives of
pediatric patients and parents. We benchmarked each of
the disease clusters to healthy children data.
Methods
Selection of samples
Ten disease clusters were composed with physician-diag-
nosed chronic conditions. These ten disease clusters,
which were compiled from a number of separate studies
[16-31], consisted of over 2,500 pediatric patients and
comprised some of the more prevalent pediatric chronic
conditions. For several disease clusters only one disease
category was available (e.g., asthma). For those disease
categories, we examined disease severity. A sample of over
9,500 healthy children derived from two separate studies
[32,33] was included to benchmark the chronic condi-
tions to healthy child data.
Procedures
Data collection across the chronic condition and healthy
samples took place during a 7 year period from 2000 to
2006. For in-person mode of administration, research
assistants obtained written parental informed consent
and child assent. The PedsQL™ was self-administered for
parents and for children ages 8 to 18 and interview-
administered for children ages 5 to 7 and in situations in
which the child was unable to read or write as a conse-
quence of either physical or cognitive impairment. For tel-
ephone administration, parents of children ages 2 to 18
were called by a research assistant who explained the
study, and obtained verbal parental informed consent.
Child assent was obtained for children ages 5 to 18 years.
The research assistant verbally administered the PedsQL™
individually to the parent and their child. If the child was
not home at the time of the initial call, the research assist-
ant arranged for a call at another time. For mail mode of
administration, parents and children ages 8–18 were
instructed to complete the PedsQL™ separately, while par-
ents of children ages 5–7 were instructed to assist their
child in completing the survey after completing the proxy-
report. These research protocols were approved by the
appropriate local Institutional Review Boards (IRBs).
Samples
Table 1 presents sociodemographic characteristics for
each sample.
Pediatric asthma sample
The asthma sample (n = 165) utilized for HRQOL com-
parisons across the disease clusters was derived from the
PedsQL™ 3.0 Asthma Module field test [16]. Children and
their parents were assessed in-person by a research assist-
ant at the University of Kansas Medical Center and at a
summer camp sponsored by the American Lung Associa-
tion [16]. Since information on patients' asthma severityPage 2 of 15
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Table 1: Sociodemographic Characteristics.
Healthy Diabetes Cardiac Asthmaa Asthmab ESRD Psych. Cancer Rheum. CP Obesityc GI
Characteristics
Self-Report:
Mean Age¥ (SD) 9.79 (3.15) 13.65 (3.33) 11.68 (3.62) 9.58 (1.65) 13.62 (1.28) 13.54 (3.77) N/A 11.49 (4.25) 12.56 (3.45) 10.42 (3.92) 12.10 (3.00) 11.57 (3.27)
Age Range¥ 5.00–18.10 5.00–18.99 5.00–18.85 7.00–12.00 12.00–18.00 5.00–18.99 5.00–18.99 5.01–18.90 5.00–18.00 5.00–18.34 5.00–18.00
Self-Report:
Gender
Male 2836 (51.5%) 134 (44.7%) 173 (60.3%) 93 (57.1%) 69 (54.8%) 47 (55.3%) N/A 220 (55.8%) 63 (18.8%) 40 (50.6%) 57 (54.0%) 132 (47.1%)
Female 2671 (48.5%) 166 (55.3%) 114 (39.7%) 68 (41.7%) 52 (41.3%) 21 (24.7%) 173 (43.9%) 255 (75.9%) 37 (46.8%) 49 (46.0%) 148 (52.9%)
Total Sample:
Mean Age ¥ (SD) 7.83 (3.99) 13.20 (3.83) 9.21 (4.73) 9.56 (1.65) 9.04 (3.62) 12.62 (4.54) 11.30 (3.20) 9.64 (4.93) 11.44 (4.28) 8.08 (4.33) 12.10 (3.00) 11.43 (3.37)
Age Range¥ 2.00–18.10 3.00–18.99 2.07–18.85 7.00–12.00 2.00–18.00 2.46–18.99 2.01–18.99 2.38–18.90 2.00–18.00 3.04–18.34 2.00–18.00
Total Sample:
Gender
Male 4918 (51.4%) 149 (45.0%) 246 (57.7%) 93 (56.4%) 251 (54.2%) 52 (54.2%) 185 (59.7%) 326 (57.0%) 80 (20.4%) 134 (54.7%) 57 (54.0%) 136 (47.4%)
Female 4647 (48.6%) 180 (54.4%) 180 (42.2%) 69 (41.8%) 181 (39.1%) 25 (26.0%) 125 (40.3%) 245 (42.8%) 293 (74.6%) 107 (43.7%) 49 (46.0%) 151 (52.6%)
Total Sample:
Race/Ethnicity
White 14.1% 46.5% 78.4% 34.5% 26.8% 38.5% N/A 22.0% 44.8% 44.9% 26.4% 71.1%
Hispanic 61.7% 25.1 % 7.7% 5.5 % 24.2% 18.8% N/A 41.1% 19.1 % 33.9 % 59.4% 15.7%
Black 2.5% 10.6 % 8.9% 8.5% 28.7% 16.7% N/A 3.0 % 3.8 % 4.9 % 7.5% 10.1%
Asian/Pacific Islander 10.9% 8.8 % 2.1% 0.6 % N/A 1.0 % N/A 3.8 % 4.1 % 5.3 % 0.9% 0.7%
American 0.4% 1.5 % 0.0% 0.0% N/A 0.0% N/A 0.0% 0.0% 0.8 % 0.0% 0.4%
Indian/Alaskan Other 0.5% 6.0% 0.7% 3.0% 20.3% 3.1% N/A 5.8 % 2.0 % 4.1 % 5.7% 2.4%
Total Sample:
Mean SES
Index‡ (SD) N/A 42.72* (14.30) 42.13* (13.45) 42.11*~ (12.04) N/A 36.13§ (13.57) N/A† 35.43§¤ (17.82) 44.73* (14.20) 42.48* (14.26) 35.60§ (14.50) N/A
Note: ¥ = Mean age and range in years.
‡ = Total Sample Mean SES Index based on the Hollingshead SES Index.
N/A = Not Available.
 = Mean SES was unavailable for this sample, although the statewide SCHIP sample was representative of low income families (< 250% of the federal poverty level).
* = Based on the Hollingshead Index, indicates on average a middle-class family SES.
§ = Based on the Hollingshead Index, indicates on average a lower middle-class family SES.
~ = Mean socioeconomic status (SES) was unavailable for families assessed at the American Lung Association summer camp, thus SES value is based on families assessed at the University of Kansas 
Medical Center (n = 86)
¤ = Mean socioeconomic status (SES) was unavailable for families assessed at Lucile Packard Children's Hospital, Stanford, thus SES value is based on families assessed at Children's Hospital and Health 
Center, San Diego, and Childrens Hospital Los Angeles (n = 438).
† = SES reported not using Hollingshead SES Index; 33.2 % of the pediatric patients came from low SES families, 30.0 % from medium SES families, and 36.8 % from high SES families.
a = Asthma sample utilized for HRQOL comparisons across disease clusters.
b = Asthma sample utilized for HRQOL comparisons across disease categories.
c = Sociodemographic information for the obesity sample represents the clinical sample of severely obese children (n = 106) used for comparisons across disease categories, given the unavailability of 
sociodemographic information for the obese and overweight community samples. ESRD equals End Stage Renal Disease. Psych. equals Psychiatric Disorders. Rheum equals Rheumatology. CP equals 
Cerebral Palsy. GI equals Gastrointestinal Conditions.
Health and Quality of Life Outcomes 2007, 5:43 http://www.hqlo.com/content/5/1/43was unavailable for this sample, a separate asthma sample
was utilized for HRQOL disease severity comparisons.
This sample (n = 463) was derived from the initial field
test of the PedsQL™ 4.0 SF-15, a short version of the Ped-
sQL™ 4.0, and the PedsQL™ 3.0 SF-22 Asthma Module, a
short version of the Asthma Module [17]. The PedsQL™
was administered by telephone to 125 adolescents (ages
12–18) and 338 parents of patients with asthma (ages 2–
11) who had been seen for asthma care at 1 of 13 geo-
graphically dispersed clinics in the United States [17].
Asthma severity included patients with mild intermittent
asthma (n = 281, 60.7 %), mild persistent asthma (n = 96,
20.7 %), and moderate to severe persistent asthma (n =
86, 18.6 %).
Pediatric cancer sample
The cancer sample (n = 572) was derived from the Ped-
sQL™ 3.0 Cancer Module field test (n = 339, 59.3 %) [18],
the PedsQL™ Brain Tumor Module field test (n = 99, 17.3
%) [19], and a study of patients with brain tumors (n =
134, 23.4 %) [20]. The sample included patients with
brain tumors (n = 257, 44.9 %), acute lymphocytic leuke-
mia (n = 171, 29.9 %), non-Hodgkin's lymphoma (n =
20, 3.5 %), Wilm's tumor (n = 19, 3.3 %), neuroblastoma
(n = 16, 2.8 %), Hodgkin's lymphoma (n = 11, 1.9 %),
and other cancers (n = 78, 13.6 %). Children and their
parents were assessed in-person by a research assistant at
hematology/oncology centers at Children's Hospital and
Health Center, San Diego, Childrens Hospital Los Ange-
les, and Lucile Packard Children's Hospital at Stanford
[16-18].
Pediatric cardiac sample
The cardiac sample (n = 426) was derived from the Ped-
sQL™ 3.0 Cardiac Module field test [21] and the PedsQL™
4.0 field test [22]. Heart disease was categorized as: 1 =
mild disease requiring no therapy or effectively treated
non-operatively (catheter therapy); 2 = moderate disease
surgically corrected (curative) or requiring no therapy; 3 =
surgical correction (one or more procedures) with signifi-
cant residua or need for further surgery; 4 = complex or
severe disease, uncorrectable or palliated (includes single
ventricle). There were 82 patients in category 1, 143 in cat-
egory 2, 93 in category 3, and 108 in category 4. Children
and their parents were assessed in-person by a research
assistant at pediatric cardiology clinics at Cincinnati Chil-
dren's Hospital Medical Center and Children's Hospital
and Health Center, San Diego [21].
Pediatric cerebral palsy sample
The cerebral palsy sample (n = 245) was derived from the
PedsQL™ 3.0 Cerebral Palsy Module field test [23]. The
sample included patients with paraplegia (n = 73, 32.0
%), diplegia (n = 69, 30.3 %), and hemiplegia (n = 50,
21.9 %). Children and their parents were assessed in-per-
son by a research assistant at the Cerebral Palsy Clinic at
Children's Hospital and Health Center, San Diego, as well
as state medical therapy clinics in San Diego County [23].
Pediatric diabetes sample
The diabetes sample (n = 331) was derived from the Ped-
sQL™ 3.0 Diabetes Module field test [24]. The sample
included patients with Type 1 diabetes (n = 236, 71.5 %)
and Type 2 diabetes (n = 91, 27.6 %). Children and their
parents were assessed in-person by a research assistant at
pediatric endocrinology clinics at Childrens Hospital Los
Angeles and Children's Hospital and Health Center, San
Diego, or via telephone [24].
Pediatric end stage renal disease sample
The end stage renal disease sample (n = 96) included
patients with a renal transplant (n = 45, 46.9 %), and
patients receiving hemodialysis (n = 32, 33.3 %) and peri-
toneal dialysis (n = 19, 19.8 %) [25]. Children and their
parents were assessed in-person by a research assistant at
Baylor College of Medicine/Texas Children's Hospital,
Houston, Texas or Children's Mercy Hospital and Clinics,
Kansas City, Missouri [25].
Pediatric gastrointestinal conditions sample
The gastrointestinal conditions sample (n = 287) included
patients who met Rome II criteria for irritable bowel syn-
drome (n = 123, 42.9%) and functional abdominal pain
(n = 82, 28.6%), and patients with a clinical diagnosis of
an organic gastrointestinal disorder (n = 82, 28.6%) [26].
Children and their parents were assessed in-person by a
research assistant at Scott & White Regional Pediatric Gas-
troenterology Clinic, Temple, TX, Children's Hospital and
Health Center, San Diego, and the Center for Pediatric
Irritable Bowel and Motility Disorders, Morristown, NJ
[26].
Pediatric obesity sample
The obesity sample (n = 63) utilized for HRQOL compar-
isons across the disease clusters was derived from a com-
munity sample classified as obese according to Body Mass
Index (BMI) cut points [27]. In addition, a clinic sample
diagnosed as severely obese (n = 106) [28] and a commu-
nity sample of overweight children (n = 294) [27] were
compared. Children and their parents were assessed in-
person by a research assistant at an obesity clinic at Chil-
dren's Hospital and Health Center, San Diego and in-per-
son in the schools in the state of Victoria, Australia [27].
Pediatric psychiatric disorders sample
Children diagnosed with a psychiatric disorder by a clini-
cian at a general or university outpatient child psychiatric
clinic in The Netherlands, and their parents, were assessed
via mailing and in-person at a home visit [29]. The psychi-
atric disorders sample (n = 310) included patients withPage 4 of 15
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107, 48.4 %), anxiety disorders (n = 57, 25.8 %), mood
disorders (n = 29, 13.1 %), and pervasive developmental
disorders (n = 28, 12.7 %) [29]. Multiple diagnoses were
permitted. However, the diagnosis of greatest immediate
clinical significance was designated as the child's primary
diagnosis by the clinician for the purposes of the study
[29].
Pediatric rheumatology sample
The rheumatology sample (n = 393) was derived from the
PedsQL™ 3.0 Rheumatology Module field test [30] and
the PedsQL™ Multidimensional Fatigue Scale field test in
rheumatology [31]. The sample included patients with
juvenile rheumatoid arthritis (n = 105, 26.7 %), fibromy-
algia (n = 59, 15.0 %), spondyloarthritis (n = 39, 9.9 %),
systemic lupus erythematosus (n = 29, 7.4 %), and other
rheumatologic conditions (n = 157, 40.0 %). Children
and their parents were assessed in-person by a research
assistant at the pediatric rheumatology clinic at Children's
Hospital and Health Center, San Diego [31].
Healthy children sample
The healthy children sample (n = 9566) was derived from
the PedsQL™ 4.0 initial field test (n = 730, 7.6 %) [32] and
a State Children's Health Insurance Program evaluation
(n = 8836, 92.4 %) [33]. Healthy children are those chil-
dren who were assessed either in physicians' offices dur-
ing well-child checks and/or whose parents did not report
the presence of a chronic health condition. Children and
their parents from the PedsQL™ 4.0 initial field test were
assessed in-person by a research assistant at Children's
Hospital and Health Center, San Diego, or via telephone
[32]. Children and their parents from the State Children's
Health Insurance Program evaluation were assessed via
mail surveys [33].
Measures
The PedsQL™ 4.0 (Pediatric Quality of Life Inventory™ Version 4.0)
The 23-item PedsQL™ 4.0 Generic Core Scales encompass:
1) Physical Functioning (8 items), 2) Emotional Func-
tioning (5 items), 3) Social Functioning (5 items), and 4)
School Functioning (5 items), and were developed
through focus groups, cognitive interviews, pre-testing,
and field testing measurement development protocols
[8,32]. The instrument takes approximately 5 minutes to
complete [32].
The PedsQL™ Scales are comprised of parallel child self-
report and parent proxy-report formats. Child self-report
includes ages 5–7, 8–12, and 13–18 years. Parent proxy-
report includes ages 2–4 (toddler), 5–7 (young child), 8–
12 (child), and 13–18 (adolescent), and assesses parent's
perceptions of their child's HRQOL. The items for each of
the forms are essentially identical, differing in develop-
mentally appropriate language, or first or third person
tense. The instructions ask how much of a problem each
item has been during the past one month. A 5-point Likert
response scale is utilized across child self-report for ages
8–18 and parent proxy-report (0 = never a problem; 1 =
almost never a problem; 2 = sometimes a problem; 3 =
often a problem; 4 = almost always a problem). To further
increase the ease of use for the young child self-report
(ages 5–7), the response scale is reworded and simplified
to a 3-point scale (0 = not at all a problem; 2 = sometimes
a problem; 4 = a lot of a problem), with each response
choice anchored to a happy to sad faces scale [34,35].
Items are reverse-scored and linearly transformed to a 0–
100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that
higher scores indicate better HRQOL. Scale Scores are
computed as the sum of the items divided by the number
of items answered (this accounts for missing data). If
more than 50% of the items in the scale are missing, the
Scale Score is not computed. This accounts for the differ-
ences in sample sizes for scales reported in the Tables.
Although there are other strategies for imputing missing
values, this computation is consistent with the previous
PedsQL™ peer-reviewed publications, as well as other
well-established HRQOL measures [32,36,37]. The Physi-
cal Health Summary Score (8 items) is the same as the
Physical Functioning Scale. To create the Psychosocial
Health Summary Score (15 items), the mean is computed
as the sum of the items divided by the number of items
answered in the Emotional, Social, and School Function-
ing Scales.
PedsQL™ Family Information Form
The PedsQL™ Family Information Form [32], or survey
items adapted from the PedsQL™ Family Information
Form, were completed by most parents. The PedsQL™
Family Information Form contains demographic informa-
tion including the child's date of birth, gender, race/eth-
nicity, and parental education and occupation
information required to calculate the Hollingshead SES
index [38].
Statistical analyses
Influence of sociodemographic characteristics
The influence of sociodemographic characteristics
(patients' age, gender, race/ethnicity) on the PedsQL™
Total Scale Score were examined for each disease cluster
(with the exception of the psychiatric disorders cluster, in
which these data were unavailable) using independent
samples t-tests and analysis of variance with Tukey post-
hoc tests.
Comparisons across disease clusters and a healthy sample
Mean PedsQL™ scale and summary scores were calculated
for each disease cluster and a healthy sample and com-Page 5 of 15
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Effect size as utilized in these analyses was calculated by
taking the difference between each disease cluster mean
and the healthy sample mean, divided by the healthy sam-
ple standard deviation. Effect sizes for differences in
means are designated as small (.20), medium (.50), and
large (.80) in magnitude [39].
Comparison of disease categories/severities within their respective 
disease clusters
Mean PedsQL™ scale and summary scores were calculated
for each disease category/severity and compared within
their respective disease cluster using independent samples
t-tests when 2 disease categories were being contrasted
and analysis of variance with Tukey post-hoc tests when
more than 2 disease categories were being contrasted.
Results
Influence of sociodemographic characteristics
Age
Adolescents in the cardiac cluster reported significantly
higher HRQOL than young children, and young children
in the asthma and gastrointestinal clusters reported signif-
icantly higher HRQOL than older children. Young chil-
dren and older children in the gastrointestinal cluster
reported significantly higher HRQOL than adolescents.
Parents reported significantly higher HRQOL for toddlers
than older children and adolescents in the diabetes, car-
diac, cancer, and rheumatology clusters.
Gender
No gender effects were found.
Race/ethnicity
No race/ethnicity effects were found for patient self-
report. Parents proxy-reported several race/ethnicity dif-
ferences across 3 disease clusters (diabetes, cardiac,
asthma), which did not achieve statistical significance
after a Bonferroni correction.
Comparisons across disease clusters and with a healthy 
sample
Overall HRQOL
Patients and parents across the disease clusters reported
significantly lower overall HRQOL in comparison to
healthy children and their parents (Tables 2 and 3). The
majority of differences for patient self-report demonstrate
medium to large effect sizes, while the majority of differ-
ences for parent proxy-report demonstrate large effect
sizes. Patients in the diabetes cluster self-reported the
highest overall HRQOL and parents proxy-reported the
highest overall patient HRQOL for the cardiac cluster.
Patients and parents in the cerebral palsy cluster reported
the lowest overall HRQOL.
Physical health
Patients across the disease clusters, with the exception of
the diabetes cluster, self-reported significantly lower phys-
ical health in comparison to healthy children (Table 2).
Parents across the disease clusters, with the exception of
the diabetes and cardiac clusters, proxy-reported signifi-
cantly lower patient physical health in comparison to
healthy children (Table 3). The majority of differences for
patient-report and parent proxy-report demonstrated
medium to large effect sizes. Patients in the diabetes clus-
ter self-reported the highest physical health, while parents
proxy-reported the highest physical health for the cardiac
cluster. Patients and parents in the cerebral palsy cluster
reported the lowest overall physical health.
Psychosocial health
Patients and parents across the disease clusters reported
significantly lower overall psychosocial health in compar-
ison to healthy children and their parents (Tables 2 and
3). The majority of differences for patient-report and par-
ent proxy-report demonstrate medium to large effect sizes.
Patients in the diabetes cluster self-reported the highest
overall psychosocial health, while parents proxy-reported
the highest overall psychosocial health for the cardiac
cluster. Patients in the psychiatric cluster self-reported the
lowest psychosocial health, while parents proxy-reported
the lowest overall psychosocial health for the cerebral
palsy and psychiatric clusters.
Emotional functioning
Patients across the disease clusters, with the exception of
the end stage renal disease cluster, self-reported signifi-
cantly lower emotional functioning in comparison to
healthy children (Table 2). The majority of differences
demonstrate small to medium effect sizes. Parents across
the disease clusters proxy-reported significantly lower
patient emotional functioning in comparison to healthy
children (Table 3). The majority of differences demon-
strate large effect sizes. Patients in the end stage renal dis-
ease cluster self-reported the highest emotional
functioning, while parents proxy-reported the highest
emotional functioning for the cardiac cluster. Patients and
parents in the psychiatric cluster reported the lowest emo-
tional functioning.
Social functioning
Patients across the disease clusters, with the exception of
the diabetes and gastrointestinal clusters, self-reported
significantly lower social functioning in comparison to
healthy children (Table 2). The majority of differences
demonstrate small to medium effect sizes. Parents across
the disease clusters, with the exception of the diabetes,
cardiac, and gastrointestinal clusters, proxy-reported sig-
nificantly lower patient social functioning in comparison
to healthy children (Table 3). The majority of these differ-Page 6 of 15
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Table 2: Child Self-Report: Means and Standard Deviations for the PedsQL™ 4.0 Generic Core Scales by Disease Cluster and Comparisons with Healthy Children Scores.
Healthya Diab.b GIc Card.d Asthmae Obesityf ESRDg Psych.h Canceri Rheum.j CPk
Scale Mean (SD) Mean (SD) 
ES
Mean (SD) 
ES
Mean (SD) 
ES
Mean (SD) 
ES
Mean (SD) 
ES
Mean (SD) 
ES
Mean (SD) 
ES
Mean (SD) 
ES
Mean (SD) 
ES
Mean (SD) 
ES
Differences
Self-Report (n = 5480) (n = 300) (n = 280) (n = 250) (n = 162) (n = 63) (n = 85) (n = 296) (n = 393) (n = 336) (n = 77)
Total Score 83.84 
(12.65)
80.35 
(12.89) 
0.28
77.79 
(13.24) 
0.48
77.47 
(14.51) 
0.50
74.85 
(16.52) 
0.71
74.00 
(14.20) 
0.78
73.97 
(15.22) 
0.78
72.20 
(12.70) 
0.92
71.97 
(16.12) 
0.94
70.35 
(17.83) 
1.07
66.85 
(16.73) 
1.34
a > b, d, e, g, h, i, j, k, f, c***; b, d > h***; h > k*; b > e, g**; b > i, j, k***; d, 
c > i, j, k***; e > j*; e > k***; g > k*; i > k*; c > h***;b > f*
Physical Health 87.53 
(13.50)
85.89 
(13.33) 
0.12
80.80 
(13.84) 
0.50
82.28 
(15.68) 
0.39
76.51 
(18.01) 
0.82
77.50 
(17.90) 
0.74
74.73 
(20.43) 
0.95
81.20 
(14.20) 
0.47
71.97 
(21.37) 
1.15
65.99 
(23.81) 
1.60
64.40 
(22.08) 
1.71
a > d, e, g, h, i, j, k, f, c***; b > h, f, c**; h > e, g*; h, c > i, j, k***; b > e, g, i, 
j, k ***; d > e, g**; d > i, j, k***; e, f > j, k***; e > i*; g > j, k***; i > j***; i > 
k**; c > g*
Psychosocial 
Health
81.87 
(14.09)
77.34 
(14.62) 
0.32
76.18 
(14.63) 
0.40
74.88 
(16.10) 
0.50
73.95 
(18.35) 
0.56
72.10 
(14.10) 
0.69
73.54 
(14.80) 
0.59
67.40 
(14.70) 
1.03
72.10 
(16.31) 
0.69
72.67 
(17.07) 
0.65
68.11 
(16.52) 
0.98
a > b, k, e, g, h, i, j, k, f, c***; b, d, e, i, j, c > h***; g > h*; b > j**; b > i, k***; 
d > k**; c > i*; c > k**
Emotional 
Functioning
79.33 
(18.15)
72.37 
(19.57) 
0.38
73.95 
(18.76) 
0.30
73.78 
(20.38) 
0.31
72.93 
(22.58) 
0.35
68.60 
(18.50) 
0.59
75.16 
(18.88) 
0.23
61.30 
(19.50) 
0.99
72.20 
(20.84) 
0.39
68.32 
(22.85) 
0.61
68.60 
(22.93) 
0.59
a > b, k, e, h, i, j, k, f, c***; b, d, e, g, i, j, c > h***; d > j*; c > j**
Social 
Functioning
85.15 
(16.76)
85.63 
(16.24) 
0.03
84.33 
(15.77) 
0.05
78.74 
(19.52) 
0.38
78.94 
(19.79) 
0.37
72.60 
(18.20) 
0.75
78.46 
(17.79) 
0.40
73.00 
(20.40) 
0.72
75.54 
(21.09) 
0.57
80.10 
(19.10) 
0.30
70.52 
(19.26) 
0.87
a > d, e, h, i, j, k, f***; a > g*; b, j, c > h***; d > h**; e > h*; b > d, i, k***; b 
> e, j**; b > g*; d > k**; e, j > k***; j > i**; e > k*; c > d**; c > e*; c > i, k, 
f***; b > f***; j > f*
School 
Functioning
81.12 
(16.45)
74.20 
(18.08) 
0.42
70.29 
(18.56) 
0.66
72.09 
(19.01) 
0.55
70.00 
(21.44) 
0.68
75.00 
(14.50) 
0.37
66.93 
(19.15) 
0.86
67.90 
(16.70) 
0.80
68.30 
(19.53) 
0.78
69.86 
(19.97) 
0.68
65.61 
(22.18) 
0.94
a > b, d, e, g, h, i, j, k, c***; b > h***; b > g, j, k**; b > i***; f > k*
Note: *p < .05, **p < .01, ***p < .001 based on analysis of variance with Tukey post-hoc tests.
With a Bonferroni correction for the number of comparisons, p < .005 values should be considered statistically significant.
Higher values equal better health-related quality of life. Disease clusters are ordered from left to right by decreasing overall HRQOL.
ES equals effect size.
Effect size represents the magnitude in the difference between the disease cluster and the healthy children sample.
Effect sizes are designated as small (.20), medium (.50), and large (.80).
Diab. equals Diabetes. Card. equals Cardiac. ESRD equals End Stage Renal Disease. Psych. equals Psychiatric Disorders. Rheum equals Rheumatology. CP equals Cerebral Palsy. GI equals Gastrointestinal Conditions.
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Table 3: Proxy-Report: Means and Standard Deviations for the PedsQL™ 4.0 Generic Core Scales by Disease Cluster and Comparisons with Healthy Children Scores.
Healthya Card.b Diab.c Obesityd GIe ESRDf Asthmag Rheum.h Canceri Psych.j CPk
Scale Mean 
(SD)
Mean 
(SD) ES
Mean 
(SD) ES
Mean 
(SD) ES
Mean 
(SD) ES
Mean 
(SD) ES
Mean 
(SD) ES
Mean 
(SD) ES
Mean 
(SD) ES
Mean 
(SD) ES
Mean 
(SD) ES
Differences
Proxy-
Report
(n = 
9430)
(n = 
344)
(n = 
307)
(n = 63) (n = 
286)
(n = 95) (n = 
157)
(n = 
357)
(n = 
561)
(n = 
307)
(n = 
224)
Total Score 82.70 
(15.40)
79.44 
(16.50) 
0.21
76.62 
(14.08) 
0.39
75.00 
(14.50) 
0.50
72.74 
(14.75) 
0.65
69.62 
(18.10) 
0.82
68.79 
(15.94) 
0.90
68.73 
(19.32) 
0.91
68.47 
(19.22) 
0.92
66.90 
(14.00) 
1.03
51.28 
(18.00) 
2.04
a > c, g, f, j, i, h, k, d, e***; a > b**; c, b, e > j***; c > g, i, h, k***; 
c > f**; b > g, f, i, h, k***; g, f, j, i, h, d, e > k***; b > e***; e > h*; 
d > j**
Physical 
Health
84.48 
(19.51)
83.11 
(18.73) 
0.07
82.02 
(17.20) 
0.13
76.30 
(17.60) 
0.42
76.00 
(16.96) 
0.43
71.21 
(24.24) 
0.68
72.68 
(18.39) 
0.60
64.05 
(25.01) 
1.05
67.55 
(25.07) 
0.87
80.00 
(17.70) 
0.23
43.19 
(27.59) 
2.12
a > j, d**; a > g, f, i, h, k, e***; j > g, f**; j, e > i, h, k***; b, c > g, 
f, i, h, k***; g > h, k***; f > h*; f, i, h > k***; c > e*; b > e***; d > 
h, k***; d > i*
Psychosocia
l Health
81.65 
(15.22)
77.36 
(17.27) 
0.28
73.67 
(15.34) 
0.52
73.90 
(15.30) 
0.51
71.00 
(15.58) 
0.70
68.85 
(17.62) 
0.84
66.83 
(16.68) 
0.97
71.27 
(18.49) 
0.68
69.12 
(18.41) 
0.82
59.90 
(15.30) 
1.43
55.91 
(16.98) 
1.69
a > b, c, g, f, j, i, h, k, e***; a > d**; b, c, g, f, i, h > j***; c > i**; c 
> g, k***; b > g, f, i, h, k***; g, f, i, h > k***; e > j, k***; b > e***; 
d > j, k***
Emotional 
Functioning
81.31 
(16.50)
74.69 
(20.45) 
0.40
69.16 
(18.54) 
0.74
72.60 
(17.80) 
0.53
65.19 
(19.28) 
0.98
68.74 
(19.69) 
0.76
64.81 
(20.21) 
1.00
66.52 
(22.27) 
0.90
67.57 
(20.70) 
0.83
54.40 
(18.70) 
1.63
62.73 
(19.55) 
1.13
a > b, c, g, f, j, i, h, k, d, e***; b, c, g, f, i, h, k, d, e > j***; b > c**; 
c > k**; b > g***; b > i, h, k***; i > k*; b > e***; d > k**
Social 
Functioning
83.70 
(19.43)
82.52 
(20.11) 
0.06
81.08 
(19.33) 
0.13
73.50 
(17.30) 
0.52
80.30 
(18.08) 
0.17
73.47 
(21.00) 
0.53
73.41 
(18.66) 
0.53
76.47 
(20.56) 
0.37
72.80 
(22.29) 
0.56
63.30 
(22.90) 
1.05
52.09 
(21.97) 
1.63
a > g, f, j, i, h, k, d***; b, c, g, f, i, h > j***; c > i, k***; c > g**; c > 
f*; b > g, i, k***; b > f, h**; g, f, i, h, d > k***; j > k***; e > j, i, 
k***; e > g*; d > j**; b > d**
School 
Functioning
78.83 
(19.59)
73.09 
(20.35) 
0.29
70.62 
(19.37) 
0.42
76.60 
(17.00) 
0.11
67.44 
(20.06) 
0.58
63.18 
(21.39) 
0.80
62.36 
(20.61) 
0.84
70.61 
(22.43) 
0.42
66.16 
(23.33) 
0.65
62.40 
(18.20) 
0.84
51.98 
(21.41) 
1.37
a > b, c, g, f, j, i, h, k, e***; b, c, h > j***; b, c, g, f, j, i, h, d, e > 
k***; c > g**; c > f*; b > g, i***; b > f**; h > g***; h > f, i*; b, d > 
e*; d > g, j***; d > f**
Note: *p < .05, **p < .01, ***p < .001 based on analysis of variance with Tukey post-hoc tests.
With a Bonferroni correction for the number of comparisons, p < .005 values should be considered statistically significant.
Higher values equal better health-related quality of life. Disease clusters are ordered from left to right by decreasing overall HRQOL.
ES equals effect size.
Effect size represents the magnitude in the difference between the disease cluster and the healthy children sample.
Effect sizes are designated as small (.20), medium (.50), and large (.80).
Diabetes. Card. equals Cardiac. ESRD equals End Stage Renal Disease. Psych. equals Psychiatric Disorders s Rheumatology. CP equals Cerebral Palsy. GI equals Gastrointestinal Conditions.
Health and Quality of Life Outcomes 2007, 5:43 http://www.hqlo.com/content/5/1/43ences demonstrate medium to large effect sizes. Patients
in the diabetes cluster self-reported the highest social
functioning, while parents proxy-reported the highest
social functioning for the cardiac cluster. Patients and par-
ents in the cerebral palsy cluster reported the lowest social
functioning.
School Functioning
Patients and parents across the disease clusters, with the
exception of the obesity cluster, reported significantly
lower school functioning in comparison to healthy chil-
dren and their parents (Tables 2 and 3). The majority of
differences demonstrate medium to large effect sizes.
Patients in the obesity and diabetes clusters self-reported
the highest school functioning, while parents proxy-
reported the highest school functioning for the obesity
cluster. Patients and parents in the cerebral palsy cluster
reported the lowest overall school functioning.
Comparison of disease categories within disease clusters 
and disease severity within disease categories
Pediatric asthma
Patients with moderate to severe persistent asthma self-
reported significantly lower overall HRQOL, physical
health, psychosocial health, emotional functioning, and
school functioning in comparison to patients with mild
intermittent and mild persistent asthma (Table 4).
Patients with moderate to severe persistent asthma self-
reported significantly lower social functioning in compar-
ison to patients with mild intermittent asthma. Patients
with mild intermittent asthma self-reported the highest
overall HRQOL.
Parents of patients with mild persistent and moderate to
severe persistent asthma proxy-reported significantly
lower patient overall HRQOL, physical health, psychoso-
cial health, emotional functioning, and school function-
ing in comparison to patients with mild intermittent
asthma (Table 5). Parents of patients with moderate to
severe persistent asthma proxy-reported significantly
lower social functioning in comparison to patients with
mild intermittent asthma. Parents of patients with mild
intermittent asthma proxy-reported the highest overall
patient HRQOL.
Pediatric cancer
Disease category comparisons in the cancer cluster were
between the two most prevalent forms of pediatric cancer,
acute lymphoblastic leukemia and brain tumors. Patients
with acute lymphoblastic leukemia self-reported no sig-
nificant HRQOL differences compared to patients with
brain tumors (Table 4). Patients with newly-diagnosed
cancer on-treatment versus long-term survivors off-treat-
ment > 12 months were also compared. Patients newly-
diagnosed receiving cancer treatment self-reported signif-
icantly lower overall HRQOL, physical health, psychoso-
cial health, and emotional functioning in comparison to
long-term survivors.
Parents of patients with brain tumors proxy-reported sig-
nificantly lower overall HRQOL, physical health, psycho-
social health, and social functioning in comparison to
pediatric patients with acute lymphoblastic leukemia
(Table 5). Parents of patients with newly-diagnosed can-
cer on-treatment reported significantly lower overall
HRQOL, physical health, psychosocial health, and emo-
tional functioning in comparison to long-term survivors.
Pediatric cardiac conditions
Patients in disease severity group 4 self-reported signifi-
cantly lower overall HRQOL in comparison to patients in
disease severity group 1. Patients in disease severity group
4 self-reported significantly lower physical health in com-
parison to patients in disease severity group 1 (Table 4).
Parents of patients in disease severity group 4 proxy-
reported significantly lower overall HRQOL, physical
health, psychosocial health, emotional functioning, social
functioning, and school functioning in comparison to
patients in disease severity group 1 (Table 5). Parents of
patients in disease severity group 4 proxy-reported signif-
icantly lower overall HRQOL, physical health, psychoso-
cial health, and social functioning in comparison to
patients in disease severity group 2. Parents of patients in
disease severity group 2 proxy-reported significantly lower
overall HRQOL, physical health, psychosocial health, and
school functioning in comparison to patients in disease
severity group 1. Parents of patients in disease severity
group 3 proxy-reported significantly lower overall
HRQOL, physical health, psychosocial health, and social
functioning in comparison to patients in disease severity
group 1.
Pediatric cerebral palsy
Patients with paraplegia self-reported significantly lower
overall HRQOL, physical health, and psychosocial health
in comparison to patients with hemiplegia (Table 4).
Patients with paraplegia self-reported significantly lower
overall HRQOL and physical health in comparison to
patients with diplegia. Patients with diplegia self-reported
significantly lower physical health in comparison to
patients with hemiplegia.
Parents of patients with paraplegia proxy-reported signifi-
cantly lower overall HRQOL, physical health, and school
functioning in comparison to pediatric patients with
hemiplegia and diplegia (Table 5).Page 9 of 15
(page number not for citation purposes)
H
e a
l t h
 a
n d
 Q
u a
l i t
y  
o f
 L
i f e
 O
u t
c o
m
e s
 2
0 0
7 ,
 5
: 4
3
h t
t p
: / /
w
w
w
. h
q l
o .
c o
m
/ c
o n
t e
n t
/ 5
/ 1
/ 4
3
P a
g e
 1
0  
o f
 1
5
( p
a g
e  
n u
m
b e
r  
n o
t  f
o r
 c
i t a
t i o
n  
p u
r p
o s
e s
)
Table 4: Child Self-Report: Means and Standard Deviations for the PedsQL™ 4.0 Generic Core Scales by Disease Category.
Total Score Physical Health Psychosocial Health Emotional Functioning Social Functioning School Functioning
n Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Asthma
Mild Intermittenta 75 81.25 (12.68) 85.80 (16.81) 78.99 (14.58) 75.08 (19.24) 83.44 (21.60) 79.67 (20.15)
Mild Persistentb 28 73.71 (12.51) 77.95 (16.40) 71.61 (14.64) 70.09 (17.04) 78.12 (19.20) 67.26 (22.90)
Moderate to Severe Persistent c 23 59.64 (21.56) 59.57 (23.50) 59.76 (23.09) 49.18 (27.59) 70.65 (27.28) 61.93 (32.74)
Differences a > c***; b > c** a > c***; b > c** a > c***; b > c* a > c***; b > c** a > c* a > b*; a > c**
Cancer
Acute Lymphoblastic Leukemiaa 109 73.25 (16.78) 74.16 (20.59) 72.86 (17.12) 72.57 (22.98) 76.90 (20.11) 68.67 (19.88)
Brain Tumor b 194 71.04 (16.05) 71.29 (21.05) 71.02 (16.50) 72.32 (20.17) 73.00 (22.57) 67.84 (19.67)
Newly Diagnosed On-Treatment¤ 105 68.92 (15.97) 65.54 (23.14) 71.04 (15.17) 68.81 (21.24) 77.19 (18.29) 66.22 (19.60)
Long-Term Survivor Off-Treatment > 
12 months§
72 77.50 (15.30) 79.95 (18.78) 76.30 (16.04) 77.57 (20.31) 79.36 (19.77) 71.11 (18.11)
Differences § > ¤*** § > ¤*** § > ¤* § > ¤** _____ _____
Cardiac
Disease Severity Group 1 a 52 82.67 (13.98) 87.97 (13.46) 79.82 (16.28) 76.15 (21.95) 83.46 (19.24) 79.31 (16.28)
Disease Severity Group 2 b 92 76.30 (13.89) 81.45 (15.30) 73.56 (14.73) 72.09 (17.40) 77.80 (18.22) 70.82 (19.45)
Disease Severity Group 3 c 63 76.36 (15.48) 80.82 (15.66) 73.92 (18.21) 72.46 (20.79) 77.92 (21.80) 71.43 (21.30)
Disease Severity Group 4 d 78 75.81 (13.93) 78.42 (17.69) 74.41 (15.01) 74.68 (21.02) 77.66 (19.03) 70.96 (18.15)
Differences a > d* a > d** _____ _____ _____ _____
Cerebral Palsy
Hemiplegiaa 30 73.14 (12.81) 75.41 (16.97) 71.78 (13.83) 72.80 (23.43) 73.00 (17.40) 70.56 (17.02)
Diplegiab 29 68.71 (16.55) 63.95 (19.66) 71.17 (17.12) 72.50 (20.75) 73.10 (20.76) 67.93 (24.04)
Paraplegiac 11 53.86 (12.21) 45.70 (16.55) 58.20 (14.42) 57.73 (16.64) 60.00 (17.89) 57.27 (21.84)
Differences a > c**; b > c* a > b*; a > c***;b > c* a > c* _____ _____ _____
Diabetes
Type 1 a 209 81.64 (12.44) 86.66 (13.21) 78.90 (14.09) 73.99 (19.49) 86.42 (15.81) 76.59 (16.68)
Type 2 b 88 77.46 (13.68) 84.36 (13.62) 73.75 (15.52) 68.69 (19.54) 83.47 (17.29) 68.97 (20.23)
Differences a > b* _____ a > b** a > b* _____ a > b**
End Stage Renal Disease
Transplanta 39 78.94 (14.24) 80.76 (20.53) 77.86 (13.46) 79.04 (18.70) 82.31 (17.54) 72.31 (16.13)
Peritoneal Dialysisb 15 70.70 (16.53) 72.89 (15.33) 69.69 (18.66) 68.75 (22.74) 73.50 (24.38) 66.25 (18.28)
Hemodialysisc 31 69.30 (14.29) 68.04 (20.74) 69.95 (13.29) 73.39 (16.45) 76.01 (13.46) 60.48 (21.46)
Differences a > c* a > c* _____ _____ _____ _____
Gastrointestinal Conditions
Irritable Bowel Syndromea 119 77.90 (12.64) 80.49 (13.23) 76.50 (13.81) 74.93 (17.43) 84.09 (15.43) 70.59 (18.70)
Functional Abdominal Painb 81 79.98 (10.62) 82.83 (11.29) 78.46 (12.10) 75.49 (17.06) 86.17 (13.28) 73.70 (15.96)
Organic Disordersc 80 75.41 (16.01) 79.21 (16.70) 73.39 (17.60) 70.94 (21.93) 82.81 (18.40) 66.39 (20.23)
Differences _____ _____ _____ _____ _____ b > c*
Obesity
Severely Obesea 106 67.00 (16.30) 71.00 (18.80) 64.90 (17.70) 63.20 (20.10) 67.50 (25.00) 64.10 (20.40)
Obeseb 63 74.00 (14.20) 77.50 (17.90) 72.10 (14.10) 68.60 (18.50) 72.60 (18.20) 75.00 (14.50)
Overweightc 294 79.30 (12.80) 83.50 (13.00) 77.00 (14.00) 72.60 (17.70) 80.20 (16.60) 78.30 (15.50)
Differences b > a**; c > a***; c > b** c > b**; c > a***; b > a* b > a**; c > a***; c > b* c > a*** c > a***; c > b** c > a***; b > a**
Psychiatric Disorders
Attention-Deficit and Disruptive 
Behavior Disordersa
107 72.40 (12.20) 84.30 (13.20) 66.00 (14.70) 61.30 (19.50) 70.30 (21.40) 66.40 (16.20)
Anxiety Disordersb 57 71.30 (12.20) 78.60 (15.60) 67.40 (13.60) 59.00 (17.70) 74.40 (19.50) 68.90 (13.90)
Mood Disorders c 29 69.70 (13.10) 80.00 (13.30) 64.20 (15.00) 55.50 (21.70) 74.40 (22.00) 63.90 (16.40)
Pervasive Developmental Disorders d 28 69.60 (14.00) 78.50 (14.30) 64.80 (16.60) 63.80 (17.40) 63.10 (23.00) 67.60 (20.50)
Differences _____ _____ _____ _____ _____ _____
Rheumatology
Systemic Lupus Erythematosusa 29 76.95 (14.97) 76.13 (19.81) 77.46 (15.69) 70.65 (23.70) 89.44 (14.29) 73.52 (16.63)
Spondyloarthritisb 39 74.92 (18.41) 69.24 (25.10) 77.99 (17.07) 77.27 (22.24) 84.87 (19.54) 72.18 (20.96)
Juvenile Rheumatoid Arthritisc 100 73.73 (16.47) 70.88 (21.52) 75.18 (16.65) 73.13 (20.87) 78.64 (19.61) 74.27 (19.07)
Fibromyalgiad 57 55.86 (15.16) 45.40 (19.86) 61.44 (16.25) 53.77 (22.41) 74.47 (18.21) 55.74 (20.46)
Differences a, b, c > d*** a, b, c > d*** a, b, c > d*** b, c > d***; a > d* a > d** c > d***; a, b > d**
Note: *p < .05, **p < .01, ***p < .001 based on Tukey post-hoc analysis when more than 2 disease categories are being compared and independent samples t-test when 2 disease categories are being compared. Contrasts for cancer disease 
categories are for Acute Lymphoblastic Leukemiaa versus Brain Tumorband Newly Diagnosed On-Treatment ¤ versus Long Term Survivor Off-Treatment > 12 months §. Asthma contrasts are based on the PedsQL™ 4.0 SF15, a shorted version 
of the 23-item PedsQL™ 4.0 Generic Core Scales.
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Social Functioning School Functioning
Mean (SD) Mean (SD)
88.43 (17.26) 83.02 (20.97)
82.23 (18.71) 75.00 (22.76)
76.85 (24.80) 71.39 (23.34)
a > c*** a > b*; a > c**
77.00 (20.40) 68.03 (22.51)
68.43 (23.92) 65.12 (23.53)
75.58 (20.08) 63.61 (24.03)
76.28 (21.71) 68.87 (23.08)
a > b*** _____
91.38 (14.19) 80.86 (17.88)
84.55 (18.73) 72.68 (19.54)
81.66 (20.40) 72.46 (20.36)
76.17 (22.09) 68.68 (23.22)
a > c**; b > d**; a > d*** a > b*; a > d**
55.92 (24.02) 57.26 (22.56)
53.88 (20.29) 56.39 (20.40)
48.29 (20.62) 45.24 (19.65)
_____ a, b > c**
82.33 (18.78) 71.87 (19.11)
77.21 (20.70) 67.42 (20.14)
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Table 5: Parent Proxy-Report: Means and Standard Deviations for the PedsQL™ 4.0 Generic Core Scales by Disease Category.
Total Score Physical Health Psychosocial Health Emotional Functioning
n Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Asthma
Mild Intermittenta 206 86.90 (13.23) 88.80 (14.37) 85.86 (15.63) 85.60 (17.84)
Mild Persistentb 68 76.77 (16.23) 76.15 (21.40) 77.11 (16.74) 74.54 (20.58)
Moderate to Severe Persistent c 63 69.88 (16.82) 64.76 (21.93) 72.65 (18.10) 69.84 (22.30)
Differences a > b, c***; b > c* a > b, c***; b > c** a > b, c*** a > b, c***
Cancer
Acute Lymphoblastic Leukemiaa 170 71.29 (18.11) 71.20 (22.54) 71.35 (17.90) 67.57 (19.97)
Brain Tumor b 249 66.21 (19.22) 65.17 (25.24) 67.01 (18.89) 67.34 (21.11)
Newly Diagnosed On-Treatment¤ 180 66.95 (19.85) 65.00 (26.26) 68.19 (18.25) 63.26 (20.70)
Long-Term Survivor Off-Treatment > 12 
months§
94 73.64 (18.72) 74.80 (24.08) 72.95 (18.07) 72.93 (19.94)
Differences a > b**;§ > ¤** a > b*; § > ¤** a > b*; § > ¤* § > ¤***
Cardiac
Disease Severity Group 1 a 82 88.06 (12.04) 93.03 (10.39) 84.98 (14.63) 81.05 (19.23)
Disease Severity Group 2 b 143 80.50 (15.13) 84.32 (18.39) 78.28 (15.58) 75.78 (20.12)
Disease Severity Group 3 c 93 78.62 (16.21) 81.86 (18.63) 76.92 (17.57) 74.50 (20.97)
Disease Severity Group 4 d 108 73.42 (18.11) 75.37 (21.35) 72.41 (18.49) 70.10 (21.29)
Differences a > b**; a > c, d***; b > d** b > d**; a > b**; a > c, d*** a > b*; a > c**; a > d***; b > 
d*
a > d**
Cerebral Palsy
Hemiplegiaa 49 57.67 (20.00) 55.72 (25.78) 58.94 (19.45) 62.19 (21.71)
Diplegiab 67 54.03 (15.87) 47.02 (22.15) 58.01 (15.97) 63.31 (19.32)
Paraplegiac 73 44.78 (15.30) 31.88 (27.19) 52.00 (14.80) 61.31 (17.61)
Differences a > c***; b > c** a > c***; b > c** _____ _____
Diabetes
Type 1 a 226 77.31 (14.12) 82.38 (17.82) 74.53 (15.17) 69.11 (18.64)
Type 2 b 78 74.71 (14.01) 81.06 (15.64) 71.28 (15.77) 69.47 (18.26)
Differences _____ _____ _____ _____
End Stage Renal Disease
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78.56 (22.20) 66.06 (18.53)
73.42 (17.95) 69.30 (16.21)
66.13 (19.27) 56.21 (25.62)
a > c* _____
82.54 (17.34) 69.35 (20.48)
79.94 (15.20) 68.93 (17.99)
77.33 (21.29) 63.13 (20.96)
_____ _____
67.20 (26.10) 61.40 (21.50)
73.50 (17.30) 76.60 (17.00)
82.30 (16.10) 78.40 (17.10)
c > a***; c > b** b, c > a***
59.10 (22.50) 59.80 (17.80)
66.30 (25.70) 62.00 (17.80)
66.20 (18.40) 60.60 (16.70)
47.20 (20.20) 61.40 (15.80)
_____ _____
83.61 (16.79) 78.53 (17.30)
81.09 (19.17) 70.61 (18.91)
76.73 (20.89) 74.66 (22.50)
67.02 (19.70) 53.77 (20.55)
a, b, c > d* a, b > d**; c > d***
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Transplanta 45 75.57 (17.75) 78.38 (24.65) 74.14 (17.50) 75.67 (18.36)
Peritoneal Dialysisb 19 68.07 (15.02) 68.40 (20.01) 67.97 (14.79) 62.11 (17.90)
Hemodialysisc 31 61.94 (17.70) 62.52 (23.45) 61.69 (17.23) 62.74 (19.79)
Differences a > c** a > c* a > c** a > b, c*
Gastrointestinal Conditions
Irritable Bowel Syndromea 122 74.82 (14.27) 78.68 (15.83) 72.72 (15.30) 66.19 (19.61)
Functional Abdominal Painb 82 73.65 (12.23) 77.70 (15.41) 71.49 (12.87) 65.49 (16.59)
Organic Disordersc 82 68.75 (16.97) 70.31 (18.82) 67.95 (18.03) 63.41 (21.30)
Differences a > c* a > c* _____ _____
Obesity
Severely Obesea 105 63.30 (19.20) 63.60 (24.00) 63.10 (18.60) 60.90 (21.70)
Obeseb 63 75.00 (14.50) 76.30 (17.60) 73.90 (15.30) 72.60 (17.80)
Overweightc 294 80.00 (13.60) 82.60 (17.20) 76.10 (14.40) 74.90 (15.80)
Differences b, c > a***; c > b** c > b**; c > a***; b > a** b, c > a*** c > a***; b > a**
Psychiatric Disorders
Attention-Deficit and Disruptive Behavior 
Disordersa
107 65.80 (13.50) 80.30 (16.20) 58.00 (15.40) 54.90 (18.70)
Anxiety Disordersb 57 66.00 (14.20) 80.30 (17.60) 58.20 (15.10) 46.80 (16.70)
Mood Disorders c 29 65.70 (11.70) 79.20 (17.80) 58.60 (12.30) 49.10 (16.90)
Pervasive Developmental Disorders d 28 61.50 (13.10) 76.30 (22.00) 53.70 (12.40) 53.70 (14.00)
Differences _____ _____ _____ a > b**
Rheumatology
Systemic Lupus Erythematosusa 18 75.25 (17.69) 70.16 (25.35) 78.00 (15.67) 72.50 (21.71)
Spondyloarthritisb 33 73.63 (18.20) 70.08 (27.65) 75.49 (15.31) 75.00 (17.94)
Juvenile Rheumatoid Arthritisc 124 73.48 (18.95) 70.07 (24.07) 75.36 (18.13) 74.58 (19.89)
Fibromyalgiad 57 52.07 (15.17) 43.37 (19.01) 56.70 (16.41) 48.95 (19.47)
Differences a, b, c > d*** a, b, c > d*** a, b, c > d*** a, b, c > d***
Note: *p < .05, **p < .01, ***p < .001 based on Tukey post-hoc analysis when more than 2 disease categories are being compared and independent sam
compared. Contrasts for cancer disease categories are for Acute Lymphoblastic Leukemiaa versus Brain Tumorband Newly Diagnosed On-Treatment ¤ ve
§. Asthma contrasts are based on the PedsQL™ 4.0 SF15, a shorted version of the 23-item PedsQL™ 4.0 Generic Core Scales.
Table 5: Parent Proxy-Report: Means and Standard Deviations for the PedsQL™ 4.0 Generic Core Scales by Disease Category. (Continued)
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Patients with Type 2 diabetes self-reported significantly
lower overall HRQOL, psychosocial health, emotional
functioning, and school functioning in comparison to
patients with Type 1 diabetes (Table 4).
Parents of patients with Type 2 diabetes proxy-reported
significantly lower social functioning in comparison to
patients with Type 1 diabetes (Table 5).
Pediatric end stage renal disease
Patients on hemodialysis self-reported significantly lower
overall HRQOL and physical health in comparison to
patients with renal transplants (Table 4).
Parents of patients on hemodialysis proxy-reported signif-
icantly lower overall HRQOL, physical health, psychoso-
cial health, emotional functioning, and social functioning
in comparison to patients with renal transplants (Table
5). Parents of patients on peritoneal dialysis proxy-
reported significantly lower emotional functioning in
comparison to patients with renal transplants.
Pediatric gastrointestinal conditions
Patients with organic gastrointestinal disorders self-
reported significantly lower school functioning in com-
parison to patients with functional abdominal pain
(Table 4).
Parents of patients with organic gastrointestinal disorders
reported significantly lower overall HRQOL and physical
health in comparison to patients with irritable bowel syn-
drome (Table 5).
Pediatric obesity
Severely obese children self-reported significantly lower
overall HRQOL, physical health, psychosocial health, and
school functioning in comparison to obese children
(Table 4). Severely obese children self-reported signifi-
cantly lower overall HRQOL, physical health, psychoso-
cial health, emotional functioning, social functioning,
and school functioning in comparison to overweight chil-
dren. Obese children self-reported significantly lower
overall HRQOL, physical health, psychosocial health, and
social functioning in comparison to overweight children.
Parents of severely obese children proxy-reported signifi-
cantly lower overall HRQOL, physical health, psychoso-
cial health, emotional functioning, and school
functioning in comparison to obese children (Table 5).
Parents of severely obese children proxy-reported signifi-
cantly lower overall HRQOL, physical health, psychoso-
cial health, emotional functioning, social functioning,
and school functioning in comparison to overweight chil-
dren. Parents of obese children proxy-reported signifi-
cantly lower overall HRQOL, physical health, and social
functioning in comparison to overweight children.
Pediatric psychiatric disorders
Patients with psychiatric disorders self-reported no statis-
tically significant differences (Table 4).
Parents of patients with anxiety disorders proxy-reported
significantly lower emotional functioning in comparison
to patients with attention-deficit/disruptive behavior dis-
orders (Table 5).
Pediatric rheumatology
Patients with fibromyalgia self-reported lower overall
HRQOL, physical health, psychosocial health, emotional
functioning, and school functioning in comparison to
other rheumatologic conditions (Table 4). Patients with
fibromyalgia self-reported lower social functioning in
comparison to patients with systemic lupus erythemato-
sus.
Parents of patients with fibromyalgia proxy-reported
lower overall HRQOL, physical health, psychosocial
health, emotional functioning, social functioning, and
school functioning in comparison to other rheumatologic
conditions (Table 5).
Discussion
The results demonstrate differential effects of pediatric
chronic conditions on patient HRQOL across ten pediat-
ric chronic disease clusters and 33 disease categories/
severities from the perspectives of pediatric patients and
parents utilizing the PedsQL™ 4.0 Generic Core Scales.
The present study on over 2,500 pediatric patients from
10 physician-diagnosed disease clusters and 33 disease
categories/severities represents the largest single investiga-
tion of generic HRQOL across pediatric chronic health
conditions that we are aware of, and as such, makes an
important contribution to the extant literature on pediat-
ric chronic health conditions.
In the present study, pediatric patients with diabetes, gas-
trointestinal conditions, cardiac conditions, asthma,
obesity, end stage renal disease, psychiatric disorders, can-
cer, rheumatologic conditions, and cerebral palsy self-
reported progressively more impaired overall HRQOL
than healthy children, respectively, with medium to large
effect sizes. Patients with cerebral palsy self-reported the
most impaired HRQOL, while patients with diabetes self-
reported the best HRQOL. Parent proxy-reports generally
paralleled patient self-report, with several notable differ-
ences. Parents proxy-reported cardiac conditions, diabe-
tes, obesity, gastrointestinal conditions, end stage renal
disease, asthma, rheumatologic conditions, cancer, psy-
chiatric conditions, and cerebral palsy as having progres-Page 13 of 15
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children, respectively, with medium to large effect sizes.
Given the well documented evidence in both the adult
and pediatric literature that information provided by
proxy-respondents is not equivalent to that reported by
the patient [40,41], the imperfect agreement between
pediatric patient and parent perspectives on the magni-
tude of impairment across the pediatric chronic condi-
tions in the current investigation is not an unexpected
finding.
The comparisons between pediatric patients with chronic
health conditions with healthy children's PedsQL™ scores
are useful in understanding the relative clinical impact of
different pediatric chronic health conditions on HRQOL.
The extant literature on the adaptation of children with
chronic physical health conditions demonstrates that
children with chronic physical health conditions are
reported to not only experience lower physical function-
ing, but also manifest lower emotional, social, and school
functioning in comparison to healthy children [42]. The
findings from the present study indicates substantial dif-
ferences on the impact of specific chronic conditions on
HRQOL, with differential impacts on physical, emo-
tional, social, and school functioning.
The challenge for health care is to identify and enroll pedi-
atric patients with chronic health conditions in high qual-
ity evidence-based comprehensive healthcare services in
order to mitigate the potential long-term negative conse-
quences on patient HRQOL. For some chronic health con-
ditions such as fibromyalgia, HRQOL and symptom
scales completed by patients may be the only indicators of
disease activity and treatment effect [43-45]. In such
patient populations, patient-reported HRQOL is often
indicated as the primary end-points for clinical trials [43-
45]. In clinical practice, patient-reported HRQOL should
be a component of high quality comprehensive care [3].
There are a number of potential limitations of the study.
Working from an existing database, several disease catego-
ries and severities contained small sample sizes, attenuat-
ing the statistical power to find significant differences.
Given the rather low prevalence rate of most pediatric
chronic conditions, we did not have the sample size to
match samples for age, gender, race/ethnicity, and SES.
Given the requirements of the local IRBs, information on
nonparticipants was not available, nor was the nonre-
sponse rates across samples, which may limit the general-
izability of the findings. Finally, we did not match the
pediatric patient and parent proxy-report databases as par-
ent/child dyads since we anticipated that there would cir-
cumstances when children were too young (i.e., under age
5), too cognitively impaired, too ill or fatigued to com-
plete a HRQOL instrument, and consequently, there
would be individual patients and groups of patients (e.g.,
pediatric patients with cerebral palsy) in which parent
proxy-report at the group level would be lower for some
dimensions given that the more severely impaired or ill
children would not being able to self-report. Future
research is indicated to investigate the various chronic
conditions under which pediatric patient self-report and
parent proxy-report are most discrepant, and the reasons
why this discrepancy might occur.
Conclusion
The data contained within this study represents a larger
and more diverse population of pediatric patients with
chronic conditions than previously reported in the extant
literature. The findings contribute important information
on the differential effects of pediatric chronic conditions
on generic HRQOL from the perspectives of children and
parents utilizing the PedsQL™ 4.0 Generic Core Scales.
These findings with the PedsQL™ have clinical implica-
tions for the healthcare services provided for children with
chronic health conditions. Given the degree of reported
impairment based on PedsQL™ scores across different
pediatric chronic conditions, the need for more effica-
cious targeted treatments for those pediatric patients with
more severely impaired HRQOL is clearly and urgently
indicated.
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